ARQ-197 (BioDeep_00000015210)

   


代谢物信息卡片


Tivantinib (ARQ 197)

化学式: C23H19N3O2 (369.1477)
中文名称: (3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮
谱图信息: 最多检出来源 Homo sapiens(not specific) 50%

分子结构信息

SMILES: C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65
InChI: InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

同义名列表

3 个代谢物同义名

Tivantinib (ARQ 197); Tivantinib; ARQ-197



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Yubin Wang, Hao Xu, Juan Yang, Juyi Zhang. The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis. Medicine. 2023 Apr; 102(16):e32591. doi: 10.1097/md.0000000000032591. [PMID: 37083791]
  • Consuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, Brian Schwartz, Sergey Orlov, Adolfo G Favaretto, Armando Santoro, Vera Hirsh, Rodryg Ramlau, Adele R Blackler, Joanna Roder, David Spigel, Silvia Novello, Wallace Akerley, Giorgio V Scagliotti. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. The oncologist. 2019 06; 24(6):e251-e259. doi: 10.1634/theoncologist.2018-0089. [PMID: 30139835]
  • Akira Naito, Seiichiro Sakao, Irene M Lang, Norbert F Voelkel, Takayuki Jujo, Keiichi Ishida, Toshihiko Sugiura, Goro Matsumiya, Ichiro Yoshino, Nobuhiro Tanabe, Koichiro Tatsumi. Endothelial cells from pulmonary endarterectomy specimens possess a high angiogenic potential and express high levels of hepatocyte growth factor. BMC pulmonary medicine. 2018 Dec; 18(1):197. doi: 10.1186/s12890-018-0769-3. [PMID: 30594174]
  • Masaya Tachibana, Kyriakos P Papadopoulos, John H Strickler, Igor Puzanov, Roohi Gajee, Yibin Wang, Hamim Zahir. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. British journal of clinical pharmacology. 2018 Jan; 84(1):112-121. doi: 10.1111/bcp.13424. [PMID: 28865153]
  • Darren L Lath, Clive H Buckle, Holly R Evans, Matthew Fisher, Jenny M Down, Michelle A Lawson, Andrew D Chantry. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PloS one. 2018; 13(6):e0199517. doi: 10.1371/journal.pone.0199517. [PMID: 29924867]
  • Christos E Kyriakopoulos, Amy M Braden, Jill M Kolesar, Jens C Eickhoff, Howard H Bailey, Jennifer Heideman, Glenn Liu, Kari B Wisinski. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Investigational new drugs. 2017 06; 35(3):290-297. doi: 10.1007/s10637-016-0418-8. [PMID: 28004284]
  • Sergio Fernández-Pello, Fabian Hofmann, Rana Tahbaz, Lorenzo Marconi, Thomas B Lam, Laurence Albiges, Karim Bensalah, Steven E Canfield, Saeed Dabestani, Rachel H Giles, Milan Hora, Markus A Kuczyk, Axel S Merseburger, Thomas Powles, Michael Staehler, Alessandro Volpe, Börje Ljungberg, Axel Bex. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European urology. 2017 03; 71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. [PMID: 27939075]
  • Yan-Li Bai, Hong-Chang Yuan, Dong-Tao Zhang, Yuan Liu, Yin Zhang. Quantitative analysis of tivantinib in rat plasma using ultra performance liquid chromatography with tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2016 Jul; 126(?):98-102. doi: 10.1016/j.jpba.2016.05.003. [PMID: 27179187]
  • Giulia Courthod, Marcello Tucci, Massimo Di Maio, Giorgio V Scagliotti. Papillary renal cell carcinoma: A review of the current therapeutic landscape. Critical reviews in oncology/hematology. 2015 Oct; 96(1):100-12. doi: 10.1016/j.critrevonc.2015.05.008. [PMID: 26052049]
  • Takuji Okusaka, Takeshi Aramaki, Yoshitaka Inaba, Shinichiro Nakamura, Manabu Morimoto, Michihisa Moriguchi, Takashi Sato, Yuta Ikawa, Masafumi Ikeda, Junji Furuse. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. Cancer science. 2015 May; 106(5):611-7. doi: 10.1111/cas.12644. [PMID: 25711511]
  • Shadia Zaman, Shujun Shentu, Jing Yang, Jin He, Robert Z Orlowski, Christine M Stellrecht, Varsha Gandhi. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia (New York, N.Y.). 2015 Mar; 17(3):289-300. doi: 10.1016/j.neo.2015.01.006. [PMID: 25810013]
  • Mark N Stein, Kim M Hirshfield, Hua Zhong, Eric A Singer, Siraj M Ali, Shridar Ganesan. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib. European urology. 2015 Feb; 67(2):353-4. doi: 10.1016/j.eururo.2014.10.012. [PMID: 25457019]
  • Takahiro Murai, Hideo Takakusa, Daisuke Nakai, Emi Kamiyama, Tomoe Taira, Tomoko Kimura, Takeshi Jimbo, Mohinder Bathala, Fraser Pickersgill, Hamim Zahir, Taro Tokui, Ronald E Savage, Mark A Ashwell, Takashi Izumi. Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats. Xenobiotica; the fate of foreign compounds in biological systems. 2014 Nov; 44(11):996-1008. doi: 10.3109/00498254.2014.926572. [PMID: 24911380]
  • G T Gibney, S A Aziz, R L Camp, P Conrad, B E Schwartz, C R Chen, W K Kelly, H M Kluger. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Feb; 24(2):343-349. doi: 10.1093/annonc/mds463. [PMID: 23022995]
  • Andrew J Wagner, John M Goldberg, Steven G Dubois, Edwin Choy, Lee Rosen, Alberto Pappo, James Geller, Ian Judson, David Hogg, Neil Senzer, Ian J Davis, Feng Chai, Carol Waghorne, Brian Schwartz, George D Demetri. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec; 118(23):5894-902. doi: 10.1002/cncr.27582. [PMID: 22605650]
  • Lee S Rosen, Neil Senzer, Tarek Mekhail, Ram Ganapathi, Feng Chai, Ronald E Savage, Carol Waghorne, Giovanni Abbadessa, Brian Schwartz, Robert Dreicer. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Dec; 17(24):7754-64. doi: 10.1158/1078-0432.ccr-11-1002. [PMID: 21976535]